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Running head: PVP versus GreenLEP in larger prostates 
ABSTRACT 
Purpose: To compare patient outcomes after 180 W XPS Greenlight photoselective 
vaporization of the prostate (PVP) and Green laser enucleation of the prostate (GreenLEP) 
used to surgically manage benign prostatic obstruction (BPO).  
Materials and Methods: Two groups of 60 consecutive patients with enlarged glands (>80 
mL) underwent either GreenLEP or PVP (performed by the same surgeon and including his 
learning curve) and were retrospectively evaluated. Perioperative data from both groups were 
compared. 
Results: Operative time was significantly shorter in the GreenLEP group (60 vs 82 min, 
p<0.0001). The complication rates were comparable between the groups. At 2 months, 
urinary incontinence was significantly higher in the GreenLEP group (25% vs. 3.4%, 
p<0.0001) but incontinence rates were similar at 6 months (3.4 % vs. 0%, p=0.50). At 6 
months, the I-PSS, QOL and PVR had similarly decreased in the two groups after the 
procedure (compared to baseline), whereas the Qmax value had greatly improved, 
significantly favoring the GreenLEP group (+78% vs. +64%, p<0.0001). The prostate size 
and PSA level reductions were significantly higher in the GreenLEP group (74% vs. 57%, 
p<0.0001 and 67% vs. 40%, p=0.007). The unplanned readmission rates were similar in both 
groups (16.7% vs. 6.7%, p=0.16). 
Conclusions: PVP and GreenLEP were safe and provided satisfactory short-term functional 
outcomes in patients with a prostate volume over 80 mL. However, the surgical time was 
longer in the PVP group, which also had a higher rate of unplanned readmission and lower 
decreases in the PSA level and prostate size. 
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INTRODUCTION
Lower urinary tract symptoms caused by benign prostatic obstruction (BPO) are highly 
prevalent in men older than 50 years of age. Surgery is indicated in cases of complicated BPO 
or moderate-to-severe symptoms with insufficient drug treatment efficacy, according to 
European guidelines.1 Greenlight photoselective vaporization of the prostate (PVP) has been 
emphasized in recent years as a viable alternative to transurethral resection of the prostate, 
with comparable short-term functional outcomes2,3 for small- to medium-sized prostates. 
However, in recent years, several studies have raised concerns regarding the efficacy of 
photoselective vaporization of the prostate (PVP) with 80 W and HPS-120 W Greenlight laser 
in larger glands with high long-term reoperation rates,4 and evidence supporting the use of the 
GreenLight XPS 180 W for PVP in larger prostates is limited. 
When prostate volumes exceed 80 mL, enucleation techniques using open prostatectomy or 
holmium-laser enucleation of the prostate (HoLEP) are currently the most established 
available options.1 HoLEP has significantly lower perioperative morbidity rates and shorter 
hospital stays, and it has favorable outcomes compared to open prostatectomy and 
transurethral resection of the prostate.1,2,5 However, to date, this technique has failed to spread 
widely in current clinical practice6 because it is technically demanding and has a long learning 
curve.7–9  
Green-laser enucleation of the prostate (GreenLEP) has recently been advocated as a new 
endoscopic enucleation procedure to excise the transitional zone as a single piece “en-bloc” 
using a Greenlight™ laser with a 120-W side firing fiber.10
However, in the literature, there is a lack of clinical data supporting GreenLEP. The aim of 
this study was to compare the efficacy of the XPS 180 W Greenlight PVP and Green laser 
“en-bloc” enucleation of the prostate (GreenLEP) procedures in relieving BPO in enlarged 
prostate volumes > 80 ml. 
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MATERIALS AND METHODS 
Population. Between April 2011 and March 2014, men who were referred for lower urinary 
tract symptoms related to BPO and who underwent surgery were retrospectively reviewed. 
The first 120 consecutive patients with a TRUS prostate measurement >80 mL who 
underwent either PVP (as previously described11) or a GreenLEP procedure were included in 
the present single-center study. There were two distinct eras during the study period: during 
the first era (2011-2012) PVP was used for all patients, regardless of the prostate volume. 
During the second era (2013-2014), we started to perform GreenLEP procedure and this 
technique was used in all patients with prostate> 80 mL. Hence, the choice between the two 
surgical techniques did not depend on patients’ characteristics.  The patients provided 
informed consent to undergo enucleation with the Greenlight™ laser. All men who underwent 
prostate cancer, and pelvic radiotherapy were excluded from the analysis. 
Surgical techniques. A Greenlight XPS 532-nm laser generator (American Medical Systems, 
Minnetonka, MN, USA) was used for all cases. The type of laser fiber used depended on 
which technique was utilized. For pure PVP, the MoXy fiber was utilized. For the GreenLEP 
group, the HPS 2090 fibers were used, along with the 120 W system. The HPS fiber was 
chosen for enucleation because it is more solid than the Moxy fiber, which allowed 
mechanical dissection of adenoma with the end of the fiber. GreenLEP was conducted with a 
Wolf™ double-flow endoscope 24.5-Fr, with continuous irrigation of the bladder with saline. 
At the end of the procedure, a morcellator with a single-use, Wolf-Piranha blade was used in 
all cases. All procedures were performed by a single surgeon (VM) with no previous 
enucleation experience. The 60 GreenLEP cases presented here indicate his learning curve. 
He learnt GreenLEP by watching videos of a proctor who had a large experience of this 
enucleation technique.10 The PVP included in this study were his first cases with prostates> 
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80 ml. 
All PVP procedures were performed as previously described with wattage from 120 to 180W 
[9]. The first step of the procedure was to identify the striated sphincter, the verumontanum, 
prostatic lobes and ureteral orifices through regular urethrocystoscopy. Then, using 
coagulation, a horizontal mark (security line) was created at the anterior part, clearly above 
the urinary sphincter. To perform 'en-bloc' enucleation of the prostate, the capsular plane was 
then found posteriorly, laterally to the verumontanum, through coagulation of the mucosa and 
then vaporization of the tissue. After the first contact with the prostatic capsule on the right 
side, enucleation was conducted from the apex and then laterally and anteriorly, primarily 
using mechanical energy by pushing the lobe towards the bladder. Occasionally, hemostasis 
(coagulation mode, power setting: 40W) or vaporization (power setting: 80W) were 
performed during this step. After the enucleation was completed laterally and anteriorly, the 
adenoma was detached in one piece and pushed into the bladder. Hemostasis was then 
performed before conventional morcellation. Only laser coagulation was routinely used. 
Electrocautery was used only in cases of uncontrolled bleeding and these procedures were 
then considered as conversion to TURP.  
Data collection. The perioperative datas were retrospectively reviewed and recorded by a 
single person (VM) using patients’ charts. Postoperative complications were also graded 
according to the Clavien–Dindo classification.12 Urinary incontinence was defined as any 
postoperative urine leakage reported by the patient. 
Postoperative follow-up assessments were scheduled postoperatively at 2, 6 and up to 12 
months. The median follow-up times were 16 [8.7; 24.7] and 6 [2.5;12] months in the PVP 
and GreenLEP groups, respectively. Hence, to make the two groups comparable (especially 
for time-dependent variables) we truncated the follow-up at 6 months.
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Statistics. Data are presented as the medians and interquartile range or mean (sd) for 
continuous variables and frequencies and percentages for qualitative variables. The Fisher 
exact test was used to compare qualitative variables, and the Wilcoxon rank-sum test was 
used to compare continuous variables, as appropriate. All tests were two-sided, and p  < 0.05 
was considered to be statistically significant. Statistical analyses were performed using R 
(version 3.1.1).  
RESULTS 
Population.  
Overall, 120 patients were included in the analysis. The median patient age, prostate volume 
and preoperative PSA were 69 range 64-76 years, 100 range 80-110 ml and 4.4 range 3-7.3 
ng/dl, respectively. The patient’s baseline characteristics are summarized in Table 1. The 
baseline clinical features were comparable between both groups, except for a significantly 
higher Qmax value, a lower PVR and a higher proportion of 2 and 3 ASA scores in the PVP 
group. No patient had undergone previous surgical treatment for BPO. One patient had 
bladder stones that were treated during the enucleation procedure (vaporization using an 
Holmium laser).  
Perioperative parameters.
PVP surgery was successfully performed in all cases, with a median of 1.12 fibers per patient 
(vs. 1.02 in the GreenLEP group, p=0.03). More than one laser fiber per procedure was 
required in 7 PVP cases due to exceeding energy limits in 3 cases and fiber damage in 4 
cases. GreenLEP surgery was performed successfully in all cases, but one patient required 
conversion to open surgery for adenoma and clot removal after the enucleation technique 
(Table 2) had been performed.  The median energy, energy/ml of prostate, lasing time and 
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intraoperative time were significantly higher in the PVP group (p<0.0001). The median time 
to catheter removal was significantly shorter in the PVP group (p<0.0001). However, both 
groups were comparable in terms of capsular perforation, early postoperative complications 
(25% vs. 16.6%, p=0.46) or median length of hospital stay (Table 2). There were 2 major 
complications in each group (Clavien IIIb). Conversion to TURP was needed in 10 and 5 
patients in the GreenLEP and the PVP group respectively (16.6% vs. 8.3%; p=0.16). 
Functional outcomes. 
At 2 and 6 months, the I-PSS, QOL and PVR had similarly decreased in the two groups after 
the procedure (compared to baseline), whereas the Qmax value had greatly improved, 
significantly favoring the GreenLEP group (+78% vs. +64%, p<0.0001). The median 
enucleated tissue weight was 63 gr [45;88], and the residual prostate volume was 23 ml 
[20;30] in the GreenLEP group. The median percent reduction of the TRUS estimated 
prostate size was significantly higher in the GreenLEP group (-74% vs. -57%, p<0.0001). 
Two cases (3.4%) of incidental Gleason 6 (3+3) low-grade prostate cancer of less than 5% 
(T1a) of the processed tissue were detected in patients undergoing GreenLEP. They opted for 
active surveillance (Table 2). The median percent reduction in the PSA level was 49% vs. 
82%, p<0.0001 at 2-months and 40% vs. 67%, p=0.006 at 6-months in the PVP and 
GreenLEP groups, respectively (Table 3). Postoperative urinary incontinence, which 
necessitated one or two pads/day, occurred significantly more frequently in the GreenLEP 
group at 2 months (25% vs. 3.4%, p<0.0001), but this difference was not longer significant 
postoperatively at 6 months (3.4% vs. 0%; p=0.15). Mean number of pads per day for patients 
with urinary incontience was 1.3 in the GreenLEP group and 1.5 in the PVP group (p=0.73). 
Physiotherapy was used in most patients with postoperative urinary incontinence in both 
groups (66.7% vs. 50%; p=0.99). When comparing the first 30 GreenLEP cases to the last 30 
cases, the rate of transient SUI was significantly lower in the latter group (11/30, i.e., 37% vs. 
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4/30 i.e., 13.3%; p=0.04). 
At 6 months, unplanned readmission rates were similar in both groups (16.7% vs. 6.7%, 
p=0.16). 
DISCUSSION
Recently, the use of GreenLight™ PVP has increased widely in Western countries but the 
evidence supporting the use of PVP for large prostates is limited.2,3 In addition, PVP has 
already been compared with Holmium enucleation, suggesting earlier improvements in 
storage symptoms after HoLEP13. This study is the first to report the clinical outcomes of the 
GreenLEP technique. Obviously, the use of Greenlight PVP for large glands is still 
controversial because of the high intraoperative time and the limited amount of tissue 
removed during the procedure, even when using the latest 180_W XPS device.14,15
Interestingly, we found that GreenLEP procedure was near 1.5-fold faster compared to PVP 
in large glands. Not surprisingly postoperative prostate volume (74 vs 57%; p <0.001) and 
PSA reduction (67 vs 40%; p = 0.007) was higher with GreenLEP than with PVP respectively 
and similar to that obtained after HoLEP.16 This difference reflects the larger amount of 
adenoma removed with enucleation compared to pure vaporization. In the current study, we 
found a better Qmax improvements at 2 and 6 months after GreenLEP which is consistent 
with the recent report of Elshal et al. who compared HoLEP with an hybrid PVP enucleation 
procedure in a randomized trial and showed a greater percent reduction in PSA (82.6 -90% vs. 
45.9 - 48%), and a greater percent reduction in TRUS volume (74 - 82% vs. 43.1 -52.5%) 
after HoLEP. They also observed a better Qmax improvement (24.9 -31.1 ml/s vs. 18.3 - 18.5 
ml/s) at 12 months in the enucleation arm.17 Despite its difference in Qmax, IPSS score and 
PVR were equivalent between the procedures. There was a trend towards higher conversion to 
TURP rate in the GreenLEP group, which could be related to a higher rate of intraoperative 
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bleeding compared to PVP during the initial cases. 
Several series have suggested higher long-term reoperation rates with PVP compared to those 
reported in large open prostatectomy series,4 but these series were published in the KTP-80 W 
and HPS-120 W era. In the largest multicenter retrospective study published to date,15 Hueber 
et al. have reported only 2% 2-yrs retreatment rates for prostate volumes > 80 ml after using 
Greenlight 180_W XPS PVP, but reports describing the long-term outcomes of 180 W XPS 
PVP on larger prostates are still lacking.   
Despite a well-established reputation supported by RCT trials and guidelines, the use of 
HoLEP among urologists remains rather low. One of the most important arguments advanced 
to explain this paradox has been the long learning curve of the technique. Long operating 
times, difficulty of the enucleation and incomplete morcellation were the most important 
factors encountered by beginner surgeons.18 The feasibility of Greenlight laser enucleation 
has been tested in a pilot study in which the authors tried to imitate the HoLEP technique.19
However, while the description of the technique seemed straightforward, the authors treated 
21 patients with rather medium-sized prostates (75 mL), and the energy used was 233 kJ, 
which was somewhat higher than that used in our experience and was close to what is 
required to perform regular PVP. According to our experience, the use of mechanical energy 
for enucleation, once the capsule has been reached, is the cornerstone of the enucleation 
technique with the Greenlight laser, and it explains the difference in the energy level used 
between PVP and GreenLEP. En bloc Green laser enucleation of the prostate has been 
previously described, and its learning curve could be shorter than the Holep one but is still 
under evaluation.10 Holep remains the only enucleation technique supported by high level of 
evidence studies.1
Our 25% rate of transient urinary incontinence in the GreenLEP group was similar to the rates 
reported in the literature with HoLEP (1.4–44%)2,20, and physiotherapy led to complete 
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symptom resolution. Among the 15 patients who experienced postoperative SUI, 11 cases 
occurred in the first 30 procedures, thereby suggesting a learning curve effect. The transient 
SUI rate observed during the last 30 GreenLEP (13 %) is roughly similar to that reported in 
PVP series (e.g., 11% at 6 month in the Goliath study).3 Based on our results, the transient 
SUI rate may be the major concern related to GreenLEP; therefore, further assessment of this 
parameter should be performed after more experience using this technique to determine 
whether our findings are only related to a steep learning curve or if they are indeed 
attributable to the GreenLEP technique. 
This study has several limitations that should be acknowledged. The major shortcomings of 
the current study, mostly related to its retrospective non-randomized design, are the learning 
curve assessment for the PVP and GreenLEP procedures (for the large glands), the short 
follow-up period and the lack of cost evaluations. The assessement of post-operative 
incontinence was based only on clinical interview, which is an important drawback, and the 
validity of this endpoint could therefore be called into question. The sexual function was not 
evaluated which could be regarded as a flaw. Despite the different distributions of ASA 
scores between both groups was a coincidence, it could have influenced the results observed, 
especially concerning complications. Different lasers have been used in the two groups and 
follow-up was longer in the PVP group. A longer follow-up is required to accurately assess 
the functional outcomes and reoperation rates.  
CONCLUSION 
PVP and GreenLEP were safe and provided satisfying short-term functional outcomes in 
patients with enlarged prostates. However, the operative time could be longer in the PVP 
group, with possibly lower decreases in the PSA level and prostate size. In contrast, 
GreenLEP could be associated with a longer catheterization time and a higher rate of transient 
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SUI.  
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Table 1 Preoperative baseline characteristics of patients (n=120) 
PVP (n=60) GreenLEP (n=60) p-value 
Age at the time of surgery (years) > 77] > 74] 0.11 
ASA score 
1 3 (5%) 24 (40%) 
< 0.0001 2 45 (75%) 30 (50%) 
3 12 (20%) 6 (10%) 
Preoperative PSA (ng/dl) > 7.5] 4.6 [3.0  7.0] 0.67
Preoperative Prostate volume (ml) > 110] > 120] 0.56
I-PSS > 21] > 20] 0.34
I-PSS question 8 (QOL) 5 [4.0  5.0] 4 [4.0  4.2] 0.01
Qmax (ml/sec) > 8.0] 5.2 [4.0  6.0] 0.005
PVR (ml) > 150] > 200] 0.01
Number of patients with indwelling 
catheter 11 (18.3%) 12 (20%) 0.99
Preoperative prostate medications 
Alpha blockers 55 (91.7 %) 56 (93.3 %) 0.99
5ARIs (alone or combined with alpha 
blockers) 20 (33.3%) 23 (38.3 %) 0.7
Patients on ongoing  
Aspirin 16 (26.6%) 27 (45%) 0.056
Clopidogrel 2 (3.3%) 2 (3.3%) 0.99
Anti vitamin K 5 (8.3%) 2 (3.3%) 0.44
Abbreviations: PSA: Prostate specific Antigen; I-PSS: International Prostate Symptom Score; QOL: quality of life; Q max: 
maximum urinary flow rate ;PVR: post-void residual volume  ; 5ARIS. 5 alpha-reductase inhibitor Data are given by number 
and percentage, n (%); median and [1rst;3rd quartile] 
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Table 2 Perioperative parameters of patients (n=120) 
PVP (n=60) GreenLEP (n=60) p-value 
Total energy (KJ) >580] > 95] <0.0001
Lasing time (min) > 68] > 25] <0.0001
Energy/ml prostate (KJ/ml) > 5.7] > 0.98] <0.0001
Intraoperative time (min) > 110] > 70] <0.0001
Lasing time/operative time (%) > 73] > 36] <0.0001
Conversion to monopolar TURP 5 (8.3%) 10 (16.6%) 0.16
Reason of TURP conversion   
For haemostasis 4 (6.7%) 6 (10%) 0.74
For residual prostatic tissue 1 (1.6%) 4 (6.7%) 0.36
Number of laser fibre per procedure* 1.12 (0.32) 1.02 (0.13) 0.03
Catheterization (days) > 2] > 2] <0.0001
Early postoperative complications  15 (25%) 10 (16.6%) 0.37
Clavien-Dindo classification   
I 
Fever resolving spontaneously 
Confusion 
Gross hematuria 
5 (8.3%) 
4
1
0
3 (5%) 
0
1
2
0.99
II 
Acute urinary retention
Gross hematuria 
Urinary tract infection 
8 (13.3%) 
3
2
3
5 (8.3%) 
4
1
0
IIIa 0 0 
IIIb 
Conversion to open simple prostatectomy
Two stages morcellation due to bleeding
Reoperation for blood clots removal
2 (3.3%) 
0
0
2
2 (3.3%) 
1
1
0
Capsular perforation 6 (10%) 7 (11.6%) 0.84
Blood transfusion 1 (1.6%) 1 (1.6%) 0.99
Length of stay (days) > 4] 2 > 4] 0.58
Weight of specimen (gms)  63 [45 ; 88] 
Histopathology 
BPH - 58 (96.6%) 
BPH with focal Gleason 6 (3+3) prostate 
cancer - 2 (3.4%) 
Abbreviations: TURP: Transurethral Resection of the Prostate; BPH: Benign Prostatic Hyperplasia. Data are given by 
number and percentage, n (%); median and [1rst;3rd quartile] or mean* (sd) 
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Table 3: Postoperative parameters 

 WsW;ŶсϲϬͿ 'ƌĞĞŶ>W;ŶсϲϬͿ ƉͲǀĂůƵĞ
2 months outcomes
I-PSS  4 [3 ; 6] 4.5 [3 ; 6] 0.84 
Reduction rate of I-PSS (%) ϳϬ;ϮϯͿ 71 (16) 0.62 
IPSS question 8 (QOL)  1 [1 ; 2] 1 [0 ; 2] 0.83 
Qmax  19 [16 ; 23] 25 [23 ; 27] <0.0001 
Increasing rate of Qmax (%) 64 (16) 78 (8.7) <0.0001 
PV (ml)  40 [30 ; 60] 23 [20 ; 30] <0.0001 
Reduction rate of PV (%) ϱϳ;ϭϲͿ 74 (11) <0.0001 
PVR (ml)  0 [0 ; 1.5] 0 [0 ; 5] 0.97 
PSA (ng/dl) 1.7 [1.4 ; 3.0] 0.64 [0.3 ; 1.0] <0.0001 
Reduction rate of PSA (%) 49 (29) 82 (17) <0.0001 
Urinary incontinence (%) 2 (3.4%) 15 (25%) <0.0001 
6 months outcomes 
PSA (ng/dl) 1.6 [1.0 ; 2.5] 0.66 [0.4 ; 1.9] 0.006 
Reduction rate of PSA 40 (77) 67 (46) 0.007 
Urinary incontinence 0 2 (3.4%) 0.15 
6 months-Unplanned readmissions 10 (16.7%) 4 (6.7%) 0.16 
Cause of readmission   
Acute urinary retention 2 (20%) 1 (25%) 
Gross hematuria 2 (20%) 0
2 stages morcellation 0 1 (25%) 
Uretral stricture 2 (20%) 0
Bladder neck stricture 1 (10%) 0
Urinary infection 3 (30%) 1 (25%) 
Cystoscopy (persistent overactive bladder) 0 1 (25%) 

ďďƌĞǀŝĂƚŝŽŶƐ͗/ͲW^^͗/ŶƚĞƌŶĂƚŝŽŶĂůWƌŽƐƚĂƚĞ^ǇŵƉƚŽŵ^ĐŽƌĞ͖YK>͗YƵĂůŝƚǇKĨ>ŝĨĞ͖W^͗WƌŽƐƚĂƚĞ^ƉĞĐŝĨŝĐŶƚŝŐĞŶ͖Ws͗
ƉƌŽƐƚĂƚĞǀŽůƵŵĞ͖ϱZ/^͗ϱͲĂůƉŚĂƌĞĚƵĐƚĂƐĞŝŶŚŝďŝƚŽƌ͘ĂƚĂĂƌĞŐŝǀĞŶďǇŶƵŵďĞƌĂŶĚƉĞƌĐĞŶƚĂŐĞ͕Ŷ;йͿ͖ŵĞĚŝĂŶĂŶĚ΀ϭƌƐƚ͖ϯƌĚ
ƋƵĂƌƚŝůĞ΁ŽƌŵĞĂŶΎ;ƐĚͿ

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Key definition for abbreviations 
PVP : photoselective vaporization of the prostate 
Greenlep : Green laser enucleation of the prostate 
IPSS: International Prostate Symptom Score 
PVR : Post-Void Residual volume 
Q max : maximum urinary flow rate 
PSA : Prostate Specific Antigen level 
BPO : Benign Prostatic Obstruction 
Holep : Holmium laser enucleation of the prostate 
ASA : American Society of Anesthesiology score 
PAI: Platelet-aggregation inhibitors 
AUR : Acute Urinary Retention 
SUI : stress urinary incontinence 
